Aflibercept biosimilar for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This study tests a biosimilar version of aflibercept (a drug that blocks abnormal blood vessel growth) in people with wet age-related macular degeneration. It aims to see how well the treatment works in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 45 and 90 years old.
- You must have active wet age-related macular degeneration (new blood vessels growing under the retina).
- Your eye exam and imaging must show signs of disease activity.
- Your doctor must have already decided you need an eye injection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether aflibercept injections can help when “wet” age-related macular degeneration is recurring or not fully going away. It focuses on adults who have already had ranibizumab and still have measurable vision in the study eye.
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
This trial tests a higher dose of aflibercept given on a flexible schedule for people who have not yet been treated for wet age-related macular degeneration (nAMD). It aims to see if this approach is safe and effective at improving vision.
This trial tests switching to a higher dose of aflibercept for people with wet age-related macular degeneration (AMD) who have already had several standard doses. It aims to see if a higher dose works better at keeping vision stable and reducing treatments.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.